IMPACT OF P2Y12 INHIBITOR CHOICE ON 30-DAY OUTCOMES AFTER PRIMARY PCI: AN ANALYSIS FROM THE EUROMAX TRIAL

Kurt Huber,Christian W. Hamm,Arnoud W.J. van t Hof,Frédéric Lapostolle,Pierre Coste,Michel Thicoipe,Giovanni Gordini,Jacob Steinmetz,Freek W.A. Verheugt,Jennifer Adgey,Lutz Nibbe,Vojko Kanič,Peter Clemmensen,Debra Bernstein,Jayne Prats,Efthymios N. Deliargyris

IMPACT OF P2Y12 INHIBITOR CHOICE ON 30-DAY OUTCOMES AFTER PRIMARY PCI: AN ANALYSIS FROM THE EUROMAX TRIAL

2014

Kurt Huber
Christian W. Hamm
Arnoud W.J. van t Hof
Frédéric Lapostolle
Pierre Coste
Michel Thicoipe
Giovanni Gordini
Jacob Steinmetz
Freek W.A. Verheugt
Jennifer Adgey
Lutz Nibbe
Vojko Kanič
Peter Clemmensen
Debra Bernstein
Jayne Prats
Efthymios N. Deliargyris

We examined the impact of P2Y12 choice on 30-day outcomes, including stent thrombosis (ST), after primary PCI in the EUROMAX trial. Of 2198 patients, 98% received a loading dose and 89% were placed on maintenance therapy with clopidogrel (CLOP), prasugrel (PRAS) or ticagrelor (TIC) per

Keywords:

Conventional PCI
Physical therapy
Medicine
Cardiology
Internal medicine
Emergency medicine
Diabetes mellitus
P2Y12

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations